Global Etanercept Market Overview
As per MRFR analysis, the Etanercept Market Size was estimated at 17.98 (USD Billion) in 2022. The Etanercept Market Industry is expected to grow from 18.93 (USD Billion) in 2023 to 30.1 (USD Billion) by 2032. The Etanercept Market CAGR (growth rate) is expected to be around 5.29% during the forecast period (2024 - 2032).
Key Etanercept Market Trends Highlighted
It is expected that the Etanercept Market, with regard to growth opportunities, will expand at a steady rate due to the prevalence of diseases such as health disasters, especially autoimmune diseases like rheumatoid arthritis and psoriasis. As more funds are allocated to biologics with molecular engineering growing market is pushing it further. Recent patterns suggest that there has been a very instigation shift to the use of biosimilars. New products and combination therapies are clinically available, enabling patients to receive more targeted therapies. Key drivers include increased environmental awareness towards autoimmune disorders, and rise in the adoption of personalized medicines and the growth of biologics in therapeutic areas. There are opportunities associated with the treatment of new Pelosi drug delivery systems and focused drug development and unmet medical needs in the treatment of autoimmune diseases.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Etanercept Market Drivers
Etanercept Market Drivers: Rising Prevalence of Autoimmune Diseases
The rising prevalence of autoimmune diseases is a major driver of the growth of the Etanercept market. Autoimmune diseases are characterized by the immune system mistakenly attacking the body's own tissues. Etanercept is a biological medication that is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. The increasing incidence of autoimmune diseases is expected to continue to drive the demand for Etanercept in the coming years. According to the World Health Organization (WHO), autoimmune diseases affect approximately 5% of the population.In the United States, autoimmune diseases are the leading cause of disability among women aged 18-64. The rising prevalence of autoimmune diseases is due to a number of factors, including genetic predisposition, environmental triggers, and lifestyle factors. The increasing prevalence of autoimmune diseases is creating a significant unmet medical need. Etanercept is a safe and effective treatment for autoimmune diseases, and it can significantly improve the quality of life for patients.The growing demand for Etanercept is expected to drive the growth of the Etanercept market in the coming years.
Etanercept Market Drivers: Growing Awareness of Biologic Therapies
Another major driver of the growth of the Etanercept market is the growing awareness of biologic therapies. Biologic therapies, which are medications that are made from living organisms or their products, include Etanercept. Unlike traditional chemical drugs, which are made from a chemical synthesis, biological therapies are composed of natural elements. The growing awareness of biological therapies is due to a number of reasons. Firstly, the prevalence of autoimmune diseases is on the rise.Secondly, new and more efficient biological therapies are continuously made. Thirdly, there is an increasing availability of information on biological therapies. Through such publications as Economic Burden of Autoimmune Disease, more people are learning about biologic therapies. The growing awareness of biological therapies is expected to drive the demand for Etanercept in the years to come. It is also creating an opportunity for the growth of the Etanercept market.Etanercept is safe and efficient and can significantly improve the quality of life of patients who have autoimmune diseases. The increasing demand for Etanercept is expected to drive the growth of the Etanercept market in the years to come.
Etanercept Market Drivers: Government Support for Research and Development
Another key driver of the growth of the Etanercept market is government support for research and development. Governments all over the world are investing in research and development to discover newer and more effective treatments for autoimmune diseases. Such investments are likely to result in the discovery of new Etanercept-based therapies, which will contribute to the growth of the Etanercept market. Besides this, another important factor that is driving the demand for Etanercept is that governments all over the world are providing financial aid to patients who are taking Etanercept REFERENCES.Such financial support is making Etanercept more accessible to patients, and it is most likely to drive the demand for the same in the future years. Government support for research and development is a major driver of the growth of the Etanercept market as it offers immense opportunities for the growth of the same. Etanercept is a safe and effective solution for autoimmune diseases, and it helps patients to live a better life. The fact that it is being increasingly recognized as a solution for auto-immune diseases is driving a huge demand for it, which in turn is contributing to the growth of the Etanercept market.
Etanercept Market Segment Insights
Etanercept Market Disease Indication Insights
Etanercept Market segmentation by Disease Indication into Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis provides insights into the specific disease areas where Etanercept is placed. Rheumatoid Arthritis is a chronic, inflammatory condition that primarily affects the joints. It is a debilitating disease characterized by swelling, pain, and morning stiffness with a variable course typically marked by periods of remissions and exacerbations. Etanercept has proved to be effective enough in reducing disease activities and delaying bone damage while improving the patients’ physical function in RA.In 2023, the Etanercept Market for RA was valued at 8.2 billion USD, and by the year 2032, it is estimated to rise to 10.3 billion USD, growing at a CAGR of 4.5%. Ankylosing Spondylitis is an inflammation of the spine and the sacroiliac joints. It results from the Ankylosing Spondylitis disorder and is a type of inflammatory arthritis. Etanercept is effective in relieving pain and stiffness and improving the mobility of patients suffering from AS. The Etanercept Market for AS was estimated at 2.5 billion USD in 2023 and is expected to grow by 3.2 billion by 2032, growing at a CAGR of 4.8%.Psoriatic Arthritis is an inflammatory form of arthritis that affects people suffering from psoriasis. Etanercept has proved to be effective enough in treating PsA and easing the signs and symptoms of PsA in patients, thus slowing the progression of the disease. The Etanercept Market for PsA was at 1.9 billion USD in the year 2023 and is expected to grow to 2.7 billion USD by 2032, growing at a CAGR of 5.1%.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Etanercept Market Administration Route Insights
The Etanercept market is segmented based on administration route into subcutaneous injection and intravenous injection. The subcutaneous injection segment held the largest market share in 2023 and is expected to continue to dominate the market throughout the forecast period. This growth is attributed to the convenience and ease of administration associated with subcutaneous injections. Intravenous injection, on the other hand, is expected to experience a steady growth rate during the forecast period, owing to the increasing adoption of biologics in the treatment of various chronic diseases.
Etanercept Market Dosage Form Insights
The growth of the Vials segment can be attributed to the increasing adoption of etanercept in vials due to its cost-effectiveness and ease of administration. The Etanercept Market for Prefilled Syringes is expected to reach USD 6.5 billion by 2024, growing at a CAGR of 5.8% during the forecast period. The growth of the Prefilled Syringes segment can be attributed to the increasing preference for prefilled syringes due to their convenience and ease of use. The Etanercept Market for Pens is expected to reach USD 3.0 billion by 2024, growing at a CAGR of 6.3% during the forecast period.The growth of the Pens segment can be attributed to the increasing adoption of etanercept pens due to their portability and ease of self-administration.
Etanercept Market Distribution Channel Insights
Distribution Channel Segment Insights and Overview The Etanercept Market segmentation by distribution channel comprises Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Among these, Hospital Pharmacies accounted for the largest revenue share in 2023, owing to the preference of healthcare professionals for administering Etanercept injections in a controlled hospital setting. However, Retail Pharmacies are projected to witness the highest CAGR during the forecast period, driven by increasing patient convenience and accessibility to Etanercept.Online Pharmacies are gaining traction due to the growing popularity of e-commerce and the convenience of home delivery. The Etanercept Market data suggests that the distribution channel segment will continue to play a crucial role in shaping the market growth trajectory in the coming years.
Etanercept Market Regional Insights
The Etanercept Market segmentation data suggests that North America is projected to dominate the Etanercept Market revenue in 2023 and is expected to continue its dominance throughout the forecast period 2024-2032. With a market share of 38.9% in 2023, North America is a significant region in the Etanercept Market. This dominance can be attributed to the high prevalence of autoimmune diseases, the increasing adoption of biologics, and the strong healthcare infrastructure in the region. Europe is expected to be the second-largest market, with a market share of 31.2% in 2023.The APAC region is anticipated to experience significant growth during the forecast period, owing to the rising awareness of autoimmune diseases and the increasing access to healthcare facilities. The South America and MEA regions are also expected to contribute to the overall growth of the Etanercept Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Etanercept Market Key Players And Competitive Insights
Major players in the Etanercept Market industry are constantly striving to gain a competitive edge by focusing on the development of innovative products, strategic collaborations, and acquisitions. Leading Etanercept Market players are investing heavily in research and development to expand their product portfolio and cater to evolving patient needs. The Etanercept Market industry is characterized by a high level of competition, with several key players holding significant market share. Some of the prominent players in the Etanercept Market include Amgen, Pfizer, Novartis, and Roche. These companies are actively involved in the development, manufacturing, and marketing of Etanercept, which is primarily used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.Amgen is a leading biotechnology company that holds a dominant position in the Etanercept Market.
The company's flagship product, Enbrel (etanercept), is a blockbuster drug that has been widely prescribed for the treatment of various autoimmune diseases. Amgen has a strong presence and has established a network of strategic partnerships with healthcare providers and distributors. The company's commitment to innovation and patient-centric approach has enabled it to maintain its leadership position in the Etanercept Market.Pfizer is another major player in the Etanercept Market. The company's product, Enbrel (etanercept), is marketed in collaboration with Amgen and is a key revenue generator for Pfizer. The company has a strong focus on research and development and has a robust pipeline of potential new products. Pfizer's reach and extensive marketing and distribution network enable it to effectively compete in the Etanercept Market.
Key Companies in the Etanercept Market Include
- Eli Lilly and Company
- Hoffmann la Roche
- Johnson Johnson
- Merck Co.
- Sanofi
- Biogen
- Pfizer
- Takeda Pharmaceutical Company
- Bristol Myers Squibb
- Novartis
- GlaxoSmithKline
- Celgene
- AbbVie
- Amgen
Etanercept Market Industry Developments
The Etanercept market is expected to grow from USD 18.93 billion in 2023 to USD 30.1 billion by 2032, exhibiting a CAGR of 5.29% during the forecast period. This growth is attributed to the increasing prevalence of autoimmune diseases, rising demand for biologics, and technological advancements in the development of biosimilars.Recent news developments include the launch of new biosimilar Etanercept products, such as Erelzi and Cyltezo. These products have been shown to be effective and well-tolerated, and they are expected to further drive market growth. Additionally, ongoing research and development efforts are focused on the development of next-generation Etanercept products with improved efficacy and safety profiles. These factors are expected to contribute to the continued growth of the Etanercept market in the coming years.
Etanercept Market Segmentation Insights
Etanercept Market Disease Indication Outlook
Etanercept Market Administration Route Outlook
-
- Subcutaneous Injection
- Intravenous Injection
Etanercept Market Dosage Form Outlook
-
- Vials
- Prefilled Syringes
- Pens
Etanercept Market Distribution Channel Outlook
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Etanercept Market Regional Outlook
-
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
17.98 (USD Billion) |
| Market Size 2023 |
18.93 (USD Billion) |
| Market Size 2032 |
30.1 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
5.29% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Eli Lilly and Company, Hoffmann la Roche, Johnson Johnson, Merck Co., Sanofi, Biogen, Pfizer, Takeda Pharmaceutical Company, Bristol Myers Squibb, Novartis, GlaxoSmithKline, Celgene, AbbVie, Amgen |
| Segments Covered |
Disease Indication, Administration Route, Dosage Form, Distribution Channel, Regional |
| Key Market Opportunities |
Increasing prevalence of rheumatic diseases Rising demand for biologics Growing awareness of Etanercept Expanding healthcare infrastructure in emerging markets Technological advancements in Etanercept development. |
| Key Market Dynamics |
Increased demand for biologics Rising prevalence of autoimmune diseases Technological advancements in drug development Growing government support for healthcare Strategic partnerships and collaborations |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Etanercept Market is expected to reach USD 18.93 billion in 2023.
The Etanercept Market is expected to reach USD 30.1 billion by 2032.
The Etanercept Market is expected to grow at a CAGR of 5.29% from 2024 to 2032.
North America is expected to have the largest market share in the Etanercept Market in 2023.
Rheumatoid arthritis is expected to have the largest market share in the Etanercept Market in 2023.
Some of the key competitors in the Etanercept Market include Amgen, Pfizer, and AbbVie.
The key factors driving the growth of the Etanercept Market include the increasing prevalence of autoimmune diseases, the rising demand for biologics, and the growing awareness of the benefits of etanercept.
The key challenges facing the Etanercept Market include the high cost of biologics, the potential for side effects, and the competition from biosimilars.
The key opportunities for the Etanercept Market include the development of new etanercept-based therapies, the expansion into new markets, and the growing adoption of biologics in developing countries.
The key trends in the Etanercept Market include the increasing use of biosimilars, the development of new combination therapies, and the growing adoption of personalized medicine.
